Table 4.
Factors affecting eradication rates in the first-line therapy
| Group A (S10) | Group B (T14) | |
|---|---|---|
| Univariate analyses | ||
| 23S rRNA mutation (genotypic) | ||
| No | 90.4% (331/366)† | 91.3% (336/368)‡ |
| Yes | 61.9% (26/42)† | 42.4% (14/33)‡ |
| Clarithromycin resistance (phenotypic) | ||
| Susceptible | 90.7% (331/365)† | 91.5% (335/366)‡ |
| Resistant | 62.2% (28/45)† | 44.4% (16/36)‡ |
| Metronidazole resistance (phenotypic) | ||
| Susceptible | 89.3% (276/309) | 89.5% (257/287) |
| Resistant | 82.2% (83/101) | 81.7% (94/115) |
| Amoxicillin resistance (phenotypic) | ||
| Susceptible | 87.6% (353/403) | 87.2% (348/399) |
| Resistant | 83.3% (5/6) | 100% (3/3) |
| Clarithromycin and metronidazole resistance (phenotypic) | ||
| CLA-S and Met-S | 91.1% (257/282) | 91.2% (248/272) |
| CLA-S and Met-R | 89.2% (74/83) | 92.6% (87/94) |
| CLA-R and Met-S | 70.4% (19/27) | 60% (9/15) |
| CLA-R and Met-R | 50% (9/18) | 33.3% (7/21) |
| Compliance (took at least 80% of the drugs) | ||
| Yes | 89.5% (556/621)§ | 89.5% (548/612)* |
| No | 37.9% (11/29)§ | 23.7% (9/38)* |
| Gastric ulcer | ||
| Present | 90.6% (125/138) | 84.8% (128/151) |
| Absent | 87.7% (372/424) | 87.1% (359/412) |
| Duodenal ulcer | ||
| Present | 92.3% (132/143) | 90.3% (130/144) |
| Absent | 87.1% (366/420) | 85.2% (358/420) |
| Setting | ||
| Hospital | 88.5% (347/392) | 88% (344/391)¶ |
| Community | 85.3% (220/258) | 82.2% (213/259)¶ |
| CYP2C19 polymorphism | ||
| PM | 88% (66/75) | 94.8% (73/77) |
| IM/EM | 87.8% (418/476) | 84.8% (408/481) |
| Multivariate analyses**, adjusted OR (95% CI), p value | ||
| Compliance Poor vs good |
31.2 (5.7 to 171.7), <0.001 | 58.2 (15.2 to 222.8), <0.001 |
| Clarithromycin Resistance vs no resistance |
5.6 (2.4 to 13.0), <0.001 | 17.2 (6.0 to 49.0), <0.001 |
| Metronidazole Resistance vs no resistance |
2.0 (0.9 to 4.3), 0.072 | 1.3 (0.6 to 3.2), 0.507 |
| CYP2C19 genotype PM vs IM/EM |
1.0 (0.4 to 2.9), 0.948 | 0.2 (0.0 to 1.0), 0.046 |
| Setting Community vs hospital |
1.5 (0.7 to 3.4), 0.332 | 2.4 (1.0 to 5.7), 0.06 |
†p<0.001; ‡p<0.001; §p<0.001; *p<0.001; ¶p<0.05.
**ORs in the multiple logistic regression models adjusted for clarithromycin resistance, metronidazole resistance, compliance, duodenal ulcer, gastric ulcer, setting, CYP2C19 polymorphism, age and gender.
23S rRNA, 23S ribosomal RNA; CLA, clarithromycin; EM, extensive metaboliser; IM, intermediate metaboliser; Met, metronidazole; PM, poor metaboliser; R, resistant; S, susceptible; S10, sequential therapy for 10 days; T14, triple therapy for 14 days.